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  It has been shown that QGC isolated and purified from Rumecis folium found protective effects of 
gastritis and esophagitis which EXT is an ethanol extract of it. We examined acute toxicity and the 
general pharmacological action of QGC EXT to search for any side effects of it in rats, mice, guinea 
pigs, and cats. In a single dose toxicity study, QGC EXT didn’t show toxicological effects in rats and 
mice, and the LD50 was o ver 5 g/kg in bo th animals, and there were also  no  c hanges in weight, feed  
and water intake during these toxicological experimental periods. We examined the general pharmacolo-
gical action on central controlled behavior responses, and peripheral organs including blood pressure, 
heart rate, respiration and gastrointestinal system, We found that there were no significant changes 
in body temperature, locomotors activity, stereotyped behaviors, sleeping time, and convulsion. In other 
studies, writhing reaction, normal body temperature, there did not appear to be any changes. The 
large intestine movement and electrical field stimulation-induced contraction was not changes by its 
EXT. In addition, the influences on blood pressure, heart rates, and respiration by QGC EXT were 
not found. These results indicate that QGC EXT may be very safe as a new drug, since its LD50 was 
very high over 5 g/kg and any side effects were not found.
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INTRODUCTION
  Flavonoids, which are secondary metabolites in plants, 
are considered relatively non-toxic bioactive substances and 
have diverse biological effects, such as anti-inflammatory, 
anti-oxidant, anti-allergic, hepatoprotective, anti-thrombotic, 
anti-viral and anti-carcinogenic activities [1,2]. Among the 
flavonoids, quercetin has been given special attention since 
it is an antioxidant which efficiently scavenges highly re-
active biological species such as peroxynitrite and the hy-
droxyl radical [3]. Rumecis folium is a family of polygo-
naceae and this plant was used for disinfestations, treating 
diarrhea, fever, edema, jaundice and constipation in tradi-
tionally oriental medicine. In the previous study performed. 
QGC (Quercetin-3-O-β-D-Glucuronopyranoside) was iso-
lated from a Rumecis folium through several steps, it QGC 
had a more potent effect than quercetin on the inhibition 
of experimental acute and chronic gastritis and ethanol-in-
duced gastritis in SD rats in vivo [4]. 
  The QGC EXT was extracted from Rumecis folium by 
ethanol. In previous studies, QGC EXT revealed protective 
effects on indomethacin induced gastric damage [5]. In the 
present study, to perform part of a preclinical evaluation 
of QGC EXT, the acute toxicity and general pharmaco-
logical effects of QGC EXT on general behavior, central 
nervous system, digestive system, smooth muscles, cardio-
vascular and respiratory systems were investigated.
METHODS
Animals
  Male Sprague-Dawley rats (200 g), guinea pigs (300 g), 
mice (30 g), or cats (3.5 kg) were used for the experiments. 
Animals were housed in a controlled room (temperature of 
22±20
oC, relative humidity of 50±5%), were maintained in 
a light controlled room and were given solid diet and tap 
water ad libitum. All animals were fasted over night before 
the experiment. This experiment was approved by the 
Institutional Animal Care and Use Committee of the 
Chung-Ang University Medical School.
Drugs
  QGC EXT was separated and extracted from Rumex 
aquaticus, phenylephrine, chlorpromazine, acetic acid, nap-
roxen, zolazepam, strychnine, valproic acid, BaSO4, ace-50 JM Lee, et al
tylcholine, urethane and other materials were purchased 
from Sigma Chemical Co. (St. Louis, Mo, USA).
S i n g l e  d o s e  t o x i c i t y  i n  m i c e  a n d  r a t s  
  Drugs were administered orally at a dose rate of 0.5, 1, 
2, 3, 5 g/kg in both sexes, respectively. Over the course of 
2 weeks, observations regarding the variation of physical 
states, weights, intake of feed & water, once a day or more 
by naked eyes were taken. The above parameters were 
measured before and after treatments. Dead animals were 
displayed on 4th, 7th, 10th, 14th day of observation. To 
evaluate the maximum tolerated dose, consecutive doses for 
4 days (1, 2, and 3 g/kg) were administrated orally in rats. 
The number of death animal was recorded. Autopsies were 
performed and checked hematological findings, main or-
gans weights and other phenomena (diarrhea, constipation, 
stool state, stomach mucosa, etc).
General behavior 
  The methods used were based on the procedures de-
scribed by Irwin [6] and Lee [7]. The effect of QGC EXT 
was observed on locomotor activity, writhing response, 
fighting, convulsion, tremor, exophthalmos, ptosis, piloer-
ection, tail elevation, traction, motor incoordination, muscle 
tone, catalepsy, righting reflex, pain response, pinna reflex, 
skin color, respiration, lacrimation, salivation, diarrhea, vo-
calization and death were observed. One night-fasted ani-
mals were administrated with the drugs, General actions 
about 24 items were indicated as "＋" or "－" after specific 
times. There were no changes on the 24 parameter of the 
behavior.
Muscle cooperation
  Mice were put on the Rotarod (Ugo Basile, ITALY) to dis-
cipline them. Rota rod rotation stick was upside down and 
rotated 5 times per minute described by Dunham et al. [8]. 
The time it took to fall down was measured and if the ani-
mal fell down within 2 minutes, we judged that motion hin-
drance occurred. Chlorpromazine 5 mg/kg was used as a 
positive control.
Writhing reaction test
  We put mice into the cage and beaker and adjusted them 
for 30 minutes Koster et al. [9]. Normal saline-diluted with 
0.6% acetic acid was injected into the abdominal cavity by 
0.1 ml/10 g for writhing reaction (repetition of stretching, 
squirining, abdominal constriction response). The number 
of writhing reactions was recorded 10 minutes and 20 mi-
nutes after the test. The drug was administrated before ace-
tic acid in mice administration. Considering the effective 
maintenance time from the preliminary experiment, ad-
ministration route, and methods, we observed the writhing 
reaction at the maximum-effect time. 500 mg/kg naproxen 
was administered as a positive control group.
Randall-Selitto test
  In each group 10 mice were used. According to the Randall 
and Selitto [10] method, 20% yeast suspension was injected 
into the sole and the sample was administrated orally 2 
hours later. Using the Randall-Selitto (UGO Basile, Italy) 
machine, Analgesy meter's needle was put on the foot of 
mice, and then we started a motor. When we increased the 
pressure of the needle gradually, the weight that made mice 
pull out their foot became the threshold for pain. QGC EXT 
10, 30, 50 mg/kg was administrated orally to each group, 
and then the values after 1 hr, 2 hrs were measured. 500 
mg/kg naproxen was used as a control.
Sleeping time 
  Zolazepam at 12.5 mg/kg was injected into the abdominal 
cavity after the administration of QGC EXT in animals 
through the oral route. The index losing more than 5 sec-
onds of righting reflex, estimated the start time of sleeping 
and duration of sleeping. Chlorpromazine 20 mg/kg was in-
jected into the abdominal cavity as the positive control 
group.
Strychnine induced convulsion
  Strychnine (1.5 mg/kg) was injected in abdominal cavity 
30 min after the drug was administered [11,12]. We watch-
ed for symptoms and compared them with the control 
group. The incidence of Tonic Flexion (TF), Tonic Extension 
(TE), Clonic convulsion (CL) and mortality were measured. 
Valproic acid 50 mg/kg was used as the positive control.
Body temperature
  Temperature was measured through the rectal route. 
Temperature was measured 0.5, 1.0, 2.0 and 3.0 hrs after 
the drug was administered. Chlorpromazine (20 mg/kg) was 
used as the positive control group.
Large intestine movement
  1 hour before the experiment, we chose animals which 
did not have diarrhea. 30 minutes after oral administration 
of the drug, 25% BaSO4 suspension (0.1 ml/10 g) was 
administered. Then we estimated the time of BaSO4 to 
come out and compared the control group with the test 
group.
Intestine motility
  We used cat or guinea pig low esophageal smooth muscle, 
ileum and relaxed it in a 1 ml organ bath with Krebs 
solution. The muscle strips were stimulated with a pulse 
train of 80 V in amplitude and 10 s in duration with a pulse 
duration of 1 ms through platinum wire electrodes placed 
longitudinally on either side of the strip. Acetylcholine was 
treated with various concentrations, and applied to 4 Hz 
electronic stimulation and measured the contraction using 
a polygraph chamber (Grass Instrument Co, Quincy, Mass, 
USA). Single muscle cells were isolated according to Sohn 
et al. [13] and Biancani et al. [14]. Muscle strips were in-
cubated overnight in a normal potassium-HEPES buffer 
containing collagenase. The next day we incubated the tis-
sue in a water bath at 31
oC for 30 min. After incubation, 
the digested tissue was poured out over a 360-μm Nitex 
filter mesh, rinsed in collagenase-free HEPES buffer to re-
move any trace of collagenase, and then incubated in this 
solution at 31
oC. The cells were allowed to dissociate freely 
for 10 to 20 min. Suspensions of single muscle cells were 
harvested by filtration through a 500 μm Nitex filter mesh.General Pharmacology of QGC EXT 51
Fig. 1. The effect of QGC EXT on the weight (A), feed intake (B), 
and water intake (C) in rats. Both male and female used 0.5, 1, 
2, 3, 5 g/kg in each dose, respectively. Any changes were not found 
between the treated and control groups.
Fig. 2. The effect of QGC EXT on the weight (A), feed intake (B), 
and water intake (C) in mice. Both male and female used 0.5, 1, 
2, 3, 5 g/kg in each dose, respectively. No changes were found 
among the treated and control groups.
Respiratory and cardiovascular effects
  After anesthesia with a urethane polyethylene (PE-10) 
tube was inserted to the carotid artery and femoral vein, 
blood pressure and heart rates were tested. We applied the 
physiological recording system (polygraph, Grass Instru-
ment Co., Quincy, Mass, USA) using a pneumograph to 
measure respiratory rate. Blood pressure and heart rate 
was carried out using the tachograph. As a positive control, 
phenylephrine 10 μg/kg was administered.
Statistical analysis
  Data are expressed as means±SEM. Statistical signifi-
cance was determined using a two-tailed Student’s t-test 
for paired observations or Chi-square test. A difference was 
considered as significant when the p value was lower than 
0.05. Traces were representative of at least three experi-
ments on three or more muscle preparations.
RESULTS
S i n g l e  d o s e  t o x i c i t y  i n  m i c e  a n d  r a t s  
  Drug at a dose rate of 0.5, 1, 2, 3, or 5 g/kg was applied 
both in male and female experimental animals, respectively. 
There were no changes in physical states, weights, intake 
of feed & water, or the recordings about the variation per-
formed once per 3∼4 days (Fig. 1 of rats, Fig. 2 of mice). 
We found that LD50 was larger than 5 g/kg in both mice 
and rats. Dead animals and these data were recorded on 
the 1
st, 3
rd, 5
th, 7
th, 9
th, 11
th, 13
th, 15
th of the observation. 
We found no dead animals with regards to every dose in 
rats and mice (Table 1 of rats and Table 2 of mice). In addi-
tion, changes of hematological findings, main organ weights 
and other phenomena (diarrhea, constipation, stool state, 
stomach mucosa) were not found. To evaluate the max-
imum tolerated dose, consecutive doses for 4 days (1, 2, and 
3 g/kg) were administered orally in rats. The number of 
dead animal was also recorded. We did not find any differ-
ences in hematological findings, main organs weights or 
other phenomena (data not shown).
General behavior
  The chronic oral administration of QGC EXT (10 mg, 30 
mg, 50 mg/kg) caused no observable change in general be-
havior responses (stereotyped behavior, convulsion, exoph-
thalmos, ptosis, piloerection, tail elevation, traction, motor 
incoordination, muscle tone, analgesia, abnormal tone, cat-
alepy, righting reflex, pinna reflex, pupil reflex, skin color, 
respiration, lacrimation, salivation, urination, diarrhea, 
death during 4 hr periods) of the rats and, compared to 
the control group, no significant changes in body weight, 52 JM Lee, et al
Table 3. Muscle cooperation
Group Dose (mg/kg. iv)
Number of mice which fell down (n=5)
Immediately 30 min 60 min 90 min 120 min 180 min 240 min
 Vehicle 0/5 0/5 0/5 0/5 0/5 0/5 0/5
 QGC EXT 10 0/5 0/5 0/5 0/5 0/5 0/5 0/5
30 0/5 0/5 0/5 0/5 0/5 0/5 0/5
50 0/5 0/5 0/5 0/5 0/5 0/5 0/5
 Positive control Chlorpromazine 10 0/5* 5/5* 5/5* 5/5* 5/5* 5/5* 5/5*
Number indicates mice which fell down. *p＜0.05; compared with vehicle treated group (Chi-square test).
Table 5. The thresholds of pain by Randall-Selitto methods
Group Dose (mg/kg) Thresholds (cm)
Vehicle 0  9.5±0.9
QGC EXT 10  9.4±0.7
30  9.3±0.6
50 10.1±0.7
Naproxen 500  15.0±1.1*
Data are expressed as mean±S.E.M. *p＜0.05 vs. control.
Table 6. Zolazepam to sleeping time
Group
Dose 
(mg/kg)
Onset time 
(min)
Sleeping time 
(min)
Vehicle 0 4.2±0.44  33.8±2.95
QGC EXT 10 5±0.70  35.2±2.39
30 3.8±0.84  28.4±16.34
50 4±2.35  26.4±1.67
Chlorpromazine 20 2±0.71 153.6±21.79*
Data are expressed as mean±S.E.M. *p＜0.05 vs. vehicle 
treatment.
Table 4. Writhing reaction
Group Dose (mg/kg) No. of writhing
Vehicle 0 18±2.55
QGC EXT 10 19.4±1.52
30 20.2±1.48
50 19.8±2.39
Naproxen 500  3.8±3.03*
Data are expressed as mean±S.E.M. *p＜0.05 vs. control. 
Vehicle: 0.6% acetic acid.
Table 1. Single dose toxicity in rats
Sex
Dose 
(g/kg)
No.
Days after treatment Mortality 
(dead/total)
LD50 
(g/kg) 013579 1 1 1 3 1 5
M a l e0 5 000000000 ( 0 / 5 ) ＞5
0 . 5 5 000000000 ( 0 / 5 )
1 5 000000000 ( 0 / 5 )
2 5 000000000 ( 0 / 5 )
3 5 000000000 ( 0 / 5 )
5 5 000000000 ( 0 / 5 )
The female group also exhibited the same results as the male 
group. LD50, 50% lethal dose.
Table 2. The single dose toxicity in mice
Sex
Dose 
(g/kg)
No.
Days after treatment Mortality 
(dead/total)
LD50 
(g/kg) 013579 1 1 1 3 1 5
Male 0 5 0 0 0 0 0 0 0 0 0 (0/5) ＞5
0.5 5 0 0 0 0 0 0 0 0 0 (0/5)
15 0 0 0 0 0 0 0 0 0( 0 / 5 )
25 0 0 0 0 0 0 0 0 0( 0 / 5 )
35 0 0 0 0 0 0 0 0 0( 0 / 5 )
55 0 0 0 0 0 0 0 0 0( 0 / 5 )
The female group also exhibited the same results as the male 
group. LD50, 50% lethal dose.
food intake and utilization of food in treated mice. Both 
the control and treated rats appeared uniformly healthy at 
the end of study.
Muscle cooperation
  Administration of QGC EXT at doses of 10 mg, 30 mg, 
50 mg/kg showed no observable changes in muscle coopera-
tion in mice at 30, 60, 90, 120, 180, 240 minutes. In con-
trast, chlorpromazine, which was a positive control, showed 
muscle cooperation disturbance (Table 3).
Writhing reaction test
  Administration of QGC EXT at doses of 10 mg, 30 mg, 
50 mg/kg showed no observable change in No. of Writhings 
in comparison with the vehicle group. However, when nap-
roxen (positive control) was treated, the No. of writhing re-
actions decreased significantly (p＜0.05) (Table 4).
Randall-Selitto test 
  Administration of QGC EXT at doses of 10 mg, 30 mg, 
50 mg/kg showed no observable change in thresholds in 
comparison with vehicle. Naproxen (positive control) in-
creased pain thresholds significantly (p＜0.05) (Table 5).
Sleeping time
  Zolazepam increased sleeping time remarkably. Admini-
stration of QGC EXT at doses of 10 mg, 30 mg, 50 mg/kg 
showed no observable change in onset time and sleeping General Pharmacology of QGC EXT 53
Table 7. Strychnine induced convulsion
Group
Dose 
(mg/kg)
Incidence/5 animals
CL TE Death
  V e h i c l e 0 5 / 5 5 / 5 5 / 5
  QGC EXT 10 5/5 5/5 5/5
30 5/5 5/5 5/5
50 5/5 5/5 5/5
  Valproic acid 50 3/5* 3/5* 2/5*
CL, clonic convulsion; TE, tonic extension. *p＜0.05; compared 
with the vehicle treated group (Chi-square test).
Table 8. Body temperatures
Time (hr.) after 
administration
Vehicle QGC EXT (mg/kg) Chloropromazine 
20 mg/kg 01 0 3 0 5 0
－0.5 37.74±0.25 37.82±0.41 37.76±0.43  38.1±0.31 37.52±0.08
  1  37.2±0.28 37.58±0.39 37.52±0.23 37.68±0.08 35.40±0.09*
  2 37.64±0.17 37.72±0.16 37.54±0.34  37.7±0.70 35.10±0.11*
  3 37.66±0.30  37.7±0.21 37.64±0.34  37.7±0.14 35.34±0.22*
Each value represents the mean±SEM, Number expressed body temperature in 
oC. *p＜0.05 vs. vehicle treatement.
Table 9. Large intestine movement
Group Dose (mg/kg)
Percentage traversed 
by BaSO4 (%)
Vehicle 0  37.4±1.79
QGC EXT 10  39.9±1.14
30 38.06±0.85
50 38.26±1.32
Each value represents the mean±SEM.
Fig. 3. The effect of QGC EXT on 
esophageal (A) and lower esophageal 
smooth muscle (B) in cats. The 
muscle strips were stretched 2.5 g. 
to bring them to near condition of 
optimal force development and equi-
librated. The contraction did not 
occur in the dose of QGC EXT 0.01, 
0.03, or 0.05 mg/ml. The contraction 
occurred in the dose of acetylcholine 
(10
－5  M) in esophageal smooth 
muscle and LES.
time. Chlorpromazine (positive control) decreased onset 
time and increased sleeping time significantly (p＜0.05) 
(Table 6).
Strychnine induced convulsion
  Strychnine induced CL and TE, and death in all cases. 
Administration of QGC EXT at doses of 10 mg, 30 mg, 50 
mg/kg showed no observable change (Table 7). Valproic acid 
prevented its convulsion. QGC EXT itself has no convulsive 
effect (data not shown).
Body temperature
  Administration of QGC EXT at doses of 10 mg, 30 mg, 
50 mg/kg showed no significant changes in body temper-
ature in mice during 240 minutes periods (Table 8).
Large intestine movement
  Administration of QGC EXT at doses of 10 mg, 30 mg, 
50 mg/kg showed no significant changes in large intestine 
movement in mice during 240 minutes periods (Table 9), 
it was the same as the vehicle treatment.
Intestine motility
  Both in cat esophageal smooth muscle and cat LES, the 
dose of QGC EXT 0.01, 0.03, 0.05 mg/ml did not cause a 
contraction (Fig. 3). When we treated with 10
－7, 10
－6, 10
－5 
M Acetylcholine to esophageal smooth muscle and LES, the 
concentration-dependent contraction was exhibited. There 54 JM Lee, et al
Table 10. The effect of QGC EXT (0.01, 0.03, 0.0.5 mg/ml) on 
EFS-induced contraction/relaxation
EFS Group (n=6)
Contraction of 
esophageal smooth 
muscle (%)
Relaxation 
of LES (%)
4 Hz Control 100±3.45 100±2.17
0.01  97±1.12 102±1.04
0.03 101±5.19  98±3.48
0.05  96±4.22 101±2.78
Each value represents the mean±SEM, EFS-Electronical Field 
Stimulation.
Table 11. The effect of QGC EXT (0.01, 0.03, 0.0.5 mg/ml) on 
agonists-induced contraction on the ileum of guinea pig
Agonists
Group 
(n=6)
Esophageal 
smooth muscle (%)
LES (%)
Acetylcholine Control 100±6.14  99±1.17
 10
－5 M 0.01  99±4.35 101±3.30
0.03 102±4.12  99±2.87
0.05  98±2.76  99±2.96
Histamine Control 100±2.14  98±2.17
 10
－4 M 0.01 100±3.35 100±1.30
0.03  99±1.12  97±2.87
0.05 101±2.76 100±0.96
Each value represents the mean±SEM.
Fig. 4. The dose response curve of acetylcholine on esophageal muscle (A) and lower esophageal sphinctor (B) in cats. Concentration-response
curves of acetylcholine were obtained either in the absence and presence of QGC EXT. Treatment of acetylcholine with 10
－7, 10
－6, 10
－5
M to esophageal smooth muscle and LES, the concentration-dependent contraction was exhibited. There was no change by treatment groupo 
with doses of 0.01, 0.03, 0.05 mg/ml QGC EXT.
was no change by treatment with 0.01, 0.03, 0.05 mg/ml 
QGC EXT (Fig. 4) Electrical stimulation induced contrac-
tions of esophageal smooth muscle and relaxation of LES 
of cats. When QGC EXT was added, there was no sig-
nificant variation (Table 10). When we used acetylcholine 
and histamine as agonists, the same result was obtained 
in guinea pigs (Table 11). The muscle strips were stretched 
2.5 gm. for optimal force development and equilibrated. 
When we treated 10
－7 M acetylcholine, the maximum con-
traction occurred at 30 second, and then the contraction 
maintained during 20 minutes. When QGC EXT was also 
added, the contraction was inhibited (Fig. 5) By electrical 
stimulation, esophageal smooth muscle exhibited the con-
traction. In contrast, LES showed the relaxation effect. EXT 
had no effect.
  We examined the effect of extracts when the maximum 
contraction was 100%. There was no effect on its own self 
like esophagus and LES. So, the response of acetylcholine 
on the contraction and relaxation was expressed as a 
percentage.
Mean blood pressure, heart rates and respiration rates
  We confirmed statistically significant vasoconstriction 
and reflective heart rate lowering effects using adrenergic 
alpha-1 agonist phenylephrine. When phenylephrine (10 μg/ 
kg i.v.) was administered, the mean blood pressure was in-
creased in 5∼10 min and recovered and sustained for sev-
eral hours (Fig. 6). With regards to heart rate, after admin-
istering the same amount of phenylephrine, it decreased 
and after 5∼10 min, it recovered and sustained itself for 
several hours (Fig. 7). There were no changes in respiration 
rates after administration of phenylephrine (Fig. 8).
DISCUSSION
  Although medicinal plants may produce several biological 
activities in humans, generally very little is known about 
their toxicity and the same applies for QGC EXT. Safety 
should be the overriding criterion in the selection of medici-
nal plants for use in healthcare systems [15]. One should, 
in addition to the use of historical documentation on QGC 
EXT, also have formal toxicological evaluation of this plant 
to optimize its safe use as a medicine.
  QGC showed potent efficacy on the development of reflux 
esophagitis and indomethacin-induced gastritis, by the in-
hibition of gastric secretion and the prevention of oxidative 
stress [16]. Flavonoids also have gastric antisecretory activ-
ity [17,18]. It has been reported that flavonoid compound 
inhibits gastric H
＋, K
＋-ATPase where the inhibition was 
competitive with respect to ATP [19,20] described the gas-General Pharmacology of QGC EXT 55
Fig. 6. The effect GQC EXT on the 
changes of mean blood pressure in 
rats. When administration of QGC 
was given at doses of 10, 30, 50 mg, 
there was no change in mean blood 
pressure. When phenylephrine 10 μg/
kg was administered the mean blood 
pressure increased in 10 minutes 
and recovered, sustaining itself for 
several hours. *p＜0.05 vs. control 
(－30 min).
Fig. 7. The effect GQC EXT on the 
changes of heart rates in rat. When 
administration of QGC was given at 
doses of 10, 30, 50 mg, there was no 
change in mean heart rate. When 
phenylephrine 10 μg/kg was admini-
stered, the mean heart rate decrea-
sed in 10 minutes and sustained it-
self for several hours afterwards. *p＜
0.05 vs. control (－30 min).
Fig. 5. The time course of Ach 10
－7 M (A), and QGC EXT (B) effect of esophageal smooth muscle of cats. When treated 10
－7 M by acetylcho-
line, the maximum contraction occurred at 30 seconds, and then maintained itself during 20 min. QGC EXT itself did not produce the 
contraction.
tric antisecretory activity is as effective as cimetidine in 
reducing gastric acid secretion. Glucuronide flavonoids have 
antiulcer and gastroprotective activity. It appeared to have 
antiulcerogenic properties in rats and guinea pigs; such 
properties appeared to be of interest with respect to the 
adverse effect of gastric ulceration, which develops com-
monly in subjects taking anti-inflammatory drugs [21]. It 
has been shown that apigenin blocked cytokine-induced ex-56 JM Lee, et al
Fig. 8. The effect of GQC EXT on the 
changes of respiration rate. When 
administration of QGC was given at 
doses of 10, 30, 50 mg, there was no 
change in respiratory rate in the 
presence or absence of phenylephrine
(10   μg/kg).
pression of intercellular adhesion molecule-1 [22,23] vas-
cular cell adhesion molecule-1, and E-selectin on human en-
dothelial cells.
  Quercetin is a natural flavone with various bioactivities. 
Quercetin was found to be highly efficient at scavenging 
free radicals in cell-free systems [24] and to be more active 
in this respect than the traditional antioxidants vitamins 
C and E [25,26] found that flavonoids, especially an apige-
nin, blocked the cytokine-induced expressions of inter-
cellular adhesion molecule-1 (ICAM-1), vascular cell adhe-
sion molecule-1 (VCAM-1), and E-selectin on human endo-
thelial cells [27]. Quercetin was also found to be an active 
anti-inflammatory agent in a rat paw carrageenan model 
and to reduce contact sensitivity in mice. In a study on gas-
tric secretion, the oral administration of QGC reduced gas-
tric content significantly and dose-dependently, and when 
QGC inhibited gastric acid output, the flavonoids exten-
sively prevented the development of reflux esophagitis. 
These results suggest that QGC has inhibitory effects on 
reflux esophagitis and gastritis in rats, and our findings 
support the antiulcer, gastroprotective, and gastric anti-se-
cretory activities of QGC. Furthermore, in feline esophageal 
epithelial cells, QGC was found to have a protective effect 
on ethanol induced cell damage by inhibiting ROS gen-
eration, activation downstream of ERK and downstream 
signal transduction induced by interleukin-1 [28].
  In this study, the extract of QGC was found to be non-tox-
ic in mice and rats when administered orally in doses up 
to 5 gm/kg. Based on the classification of Loomis and Hayes 
[29] viz. that substances with LD50 between 500 and 5,000 
and between 5,000 and 15,000 mg/kg bodyweight are re-
garded as being slightly toxic and practically non-toxic, re-
spectively, the present results suggested that GQC EET 
safety falls between these 2 categories. 
  There were no effects on the central nervous system, car-
diovascular system, gastrointestinal system, and respira-
tory system. From the data found in this experiment we 
conclude that QGC EXT did not induce any adverse effects 
in experimental animals.
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